stockrow
Saturday 7 November 2026
Export GNLX’s income statement to Excel — free account
Genelux Corporation
GNLX Healthcare Biotechnology
Genelux Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8,000.00, roughly unchanged from fiscal 2024.
- EPS
- −5.00%
- Free cash flow
- −11.2%
Quarter to June 2026, against a year earlier
1.97
0.15
+8.24%
Follow GNLX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 11 | 0 | 0 | 0 | 11 | (91.0%) | 8 | 8 | 78 | +2,032.0% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | (3.42) | +100.0 pt | ||||||
| EBT | — | — | — | (12) | (14) | (16) | (4) | (28) | (30) | (32) | (36) | +18.5% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | (37.11) | (16,645.29) | (373,362.50) | (401,812.50) | 0.00 | (401,812.5) pt | ||||||
| Net income | — | — | — | (12) | (14) | (16) | (5) | (28) | (30) | (32) | (36) | +18.5% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 1.21 | 0.01 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.49) | (0.58) | (1.81) | (0.57) | (1.16) | (0.95) | (0.86) | (0.86) | +9.8% | ||||||
| Cash flow | — | — | — | (0.31) | (0.31) | (0.73) | (0.39) | (0.83) | (0.67) | (0.68) | (0.56) | +14.2% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | (0.01) | (0.04) | (0.01) | (0.03) | (0.08) | n/m | ||||||
| Free cash flow | — | — | — | (0.31) | (0.31) | (0.73) | (0.40) | (0.87) | (0.69) | (0.71) | (0.64) | +15.0% | ||||||
| Book value | — | — | — | (1.05) | (0.96) | (3.67) | (3.93) | 0.80 | 0.84 | 0.31 | 0.36 | n/m | ||||||
| Shares, m | — | — | — | 24 | 24 | 9 | 9 | 24 | 31 | 37 | 41 | +7.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 0.00 | 6.60 | 14.41 | 7.88 | 5.3 | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 18.63 | 2.83 | 14.04 | 5.50 | 8.9 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 4.61 | 13.87 | 6.97 | 4.6 | ||||||
| EV/FCF | — | — | — | — | — | — | (17.73) | (16.34) | (2.40) | (5.92) | (2.73) | (10.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (7) | (7) | (7) | (4) | (20) | (21) | (25) | (25) | +23.2% | |||||
| Capex | — | — | — | (2) | 0 | — | 0 | (1) | 0 | (1) | (3) | (7.7%) | ||||||
| Free cash flow | — | — | — | (7) | (7) | (7) | (4) | (21) | (22) | (26) | (29) | +24.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | (14) | (3) | (17) | (30) | 18 | 25 | 9 | 11 | n/m | |||||
| Net debt | — | — | — | 18 | 15 | 13 | 8 | (23) | (31) | (15) | (19) | n/m | ||||||
| Shareholders’ equity | — | — | — | (25) | (23) | (33) | (36) | 19 | 26 | 12 | 16 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (157.82) | (147.99) | (76.25) | (169.32) | (95.41) | (119.62) | (121.80) | (119.6) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 0.00 | 57.43 | 58.69 | 15.11 | 346.52 | (130.58) | (170.00) | (177.93) | (170.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 15 | 15 | 25 | 24 | 26 | — | +14.7% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.74 | 0.01 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2024
Genelux Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MIST Milestone Pharmaceuticals Inc. | $86.2M | — (loss-making) | — (loss-making) | −62.73% (below 0%: shrinking) | n/m | −80.81% (below 0%: shrinking) | 94.28% | (4,584.97%) | Compare |
| VTVT vTv Therapeutics Inc. | $86.0M | — (loss-making) | — (loss-making) | +409,222.22% (above 0%: growing) | n/m | −124.59% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RLYB Rallybio Corporation | $84.5M | 3.3× | — (loss-making) | 0.00% | n/m | +65.25% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EQ Equillium, Inc. | $84.3M | — (loss-making) | — (loss-making) | −52.32% (below 0%: shrinking) | n/m | −38.67% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GNLX Genelux Corporation | $82.4M | — (loss-making) | — (loss-making) | — | n/m | −11.18% (below 0%: shrinking) | 100.00% | 0.00% | |
| KZIA Novogen Limited | $80.0M | — (loss-making) | — (loss-making) | — | −32.67% (below 0%: shrinking) | −51.71% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ATRA Atara Biotherapeutics, Inc. | $79.9M | — (loss-making) | — (loss-making) | −96.42% (below 0%: shrinking) | n/m | +52.10% (above 0%: growing) | 69.68% | (749.21%) | Compare |
| TLSA Tiziana Life Sciences Ltd | $79.6M | — (loss-making) | — | — | −258.11% (below 0%: shrinking) | +18.03% (above 0%: growing) | 0.00% | — | Compare |
| TNXP Tonix Pharmaceuticals Holding Corp. | $78.9M | — (loss-making) | — (loss-making) | +577.88% (above 0%: growing) | n/m | −178.84% (below 0%: shrinking) | 94.81% | (314.05%) | Compare |
| Median of peers | $82.2M | — | — | −26.16% | — | −45.19% | 94.55% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
7.50%
Armistice Capital, LLC
9.40%
Aladar Szalay, Ph.D.
7.00%
Highbridge Capital Management, LLC
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement